Melbourne-based Genetic Technologies Ltd. (GENE) reports that it received 1,096 BREVAGen test samples in its last fiscal quarter ending June 30 which was 37% more than fiscal Q3. The firm received a total of 3,935 BREVAGen samples for the fiscal year.
BREVAGen is a test that assesses a patient's percentage risk of developing breast cancer over a five-year time frame and lifetime. It combines clinical risk factors plus the individual's genetic markers (BRCA1 and BRCA2) to determine the percentage risk.
The company is on schedule to release its next generation BREVAGen test which will include an expanded SNP panel that will give it more robust predictive power. It will also be validated in the African American and Hispanic populations.